RECORDING Facing the unknowns caused by GLP-1RA medications in Binge eating disordersمواجهه التحديات و المجهول من استعمال ادويه التخسيس الجديده لعلاج اضطراب شراهه الطعام
ZOOM WEBINAR ON THURSDAY, DECEMBER 19 at 3pm/Egypt time- 8am/ USA Eastern Presented in English & Arabic by Dr. Heba Essawy MD., CEDS, International Chapter Chair of Egypt
LINK TO RECORDING – (Passcode: R!E#V81Y)
Binge Eating Disorder is a mental illness characterized by recurrent binge eating episodes in the absence of appropriate compensatory behaviors. It results from poor coping with negative affect, mood dysregulation and distress intolerance. Patients use food as an escape plan to redirect their attention from the stressor and for reinforced reduction of stress. BED is linked to obesity, low self-esteem, guilt and depression with high risk of suicide and various physical complications such as DM, hypertension, cardiac problems and cerebrovascular strokes. Detailed assessment of the neurobiological risk factors and addressing the psychopathological implications of BED are necessary to mitigate its negative consequences and morbidities. Different therapeutic modalities are implemented for improving the relation between the patient and food including E-CBT for eating disorders, Interpersonal Psychotherapy, and Dialectical Behavioral Therapy. Serotonergic antidepressants have an effective role in targeting impulsivity/compulsivity related to binge episodes, modulating both emotional reactivity and reward processing. Also we will discuss , the Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a new group of drugs that were originally developed to treat type 2 diabetes and that are increasingly prescribed to manage weight. GLP-1 RAs have been shown to be very effective at lowering blood sugar levels. However, there is a lack of evidence to inform whether GLP-1 RAs could be administered in populations with Binge eating disorders . In this webinar Dr. Essawy will provide an overview of how GLP-1RAs act in the brain to increase feeling of satiety as well as reduce hedonic aspects of eating behaviour such as craving. She will also cover what is known about the role of GLP-1 in stress and mood.
For Questions contact Dr. Essawy: essawi_h@yahoo.com
Bio
Heba Essawy MD, clinical Professor of Psychiatry, Ain Shams University Hospital, Cairo, Egypt. She has been the Medical Director of eating disorders clinics since 2013. For 28 years at the Institute of Psychiatry she has practiced writing, lecturing, supervising and directing outpatient eating disorders clinics.
She obtained her CEDS designation from iaedp™ in 2019 and became the first eating disorders certified specialist in Egypt. She is the Founder and President of First Egyptian Association for Eating Disorders. Her role has expanded treatment services to include pediatric, adolescents and adult populations. Heba is passionate about empowering and educating parents as well as their children. She maintains a private practice in psychotherapy and medication management in Cairo.
Heba has presented extensively, nationally and international conferences as well as provides campus-wide training. She has been published in academic journals and the popular media as well as contributing chapters to several books and appeared on a variety of local and national news and radio outlets.
Special Educational Partnership since October 2021
Heba Essawy, MD, CEDS and her organization, First Egyptian Association for Eating Disorders, are a Designated Educational Affiliate for iaedp™ to assist individuals in Egypt in attaining the status of Associate Designee, iaedp™ Institute on Eating Disorders.
